P284 Sex-specific aspects in IBD: a multidimensional view

L Püschel,A Alaswad,Z Liu,L Zhou,M Bathon,U Seidler,H Lenzen,H Wedemeyer,Y Li,M Wiestler
DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0414
2024-01-01
Journal of Crohn's and Colitis
Abstract:Abstract Background Inflammatory bowel diseases (IBD), including Ulcerative colitis (UC) and Crohn's disease (CD), are chronic intestinal disorders characterised by varied intestinal symptoms and a negative impact on the patients` quality of life. Increasing evidence demonstrates sex differences regarding the prevalence, pathophysiology, clinical presentation and treatment outcome of IBD. While for some factors evidence is rather good, for others data are conflicting – thus a deeper understanding of sex related differences in IBD courses is still needed. Methods In this monocentric, cross-sectional study 221 IBD patients were stratified into 2 groups according to gender/biological sex (male [n=106]; female [n=113]). We evaluated patients personal and medical data including disease-specific quality of life (IBDQ) as well as clinical (HBI, PMS) and biochemical (CRP, fecal calprotectin) parameters of disease activity. Furthermore, we isolated and stimulated PBMCs with various pathogens to test ex vivo cytokine responses of this heterogeneous IBD cohort. Results Binary logistic regression analysis suggested an independent association of diagnostic delay (p= 0.039), IBD entity (p= 0.001), IBDQ (p= 0.001), and vitamin D3-25-OH serum level (p= 0.035) with disease activity for female IBD patients, while for male IBD patients an independent association was only suggested for IBD entity (p= 0.004) and IBDQ (p= 0.001) (figure 1). Next, we tested the association between the number of ADT (Advanced Therapies) taken during the overall course of the disease with both disease activity and diagnostic delay. We found a significant association between ADT and disease activity in both sexes (male-p = 0.015, female-p=0.037), but ADT was only significantly associated with diagnostic delay in female IBD patients (p=0.044) (figure 2). Regarding the frequency of therapies used in both sexes, we found that male patients are more frequently subscribed prednisolone (Mann-Whitney-U, p= 0.009) as well as 5-ASA (p= 0.004) (figure 3). Cytokine responses upon PBMC stimulations with various pathogens showed a significant trend in Interferon gamma levels in male CD patients (p< 0.05) (figure 5A). A significant negative correlation between Interferon gamma levels and CD activity has only been found in male CD patients, but not in female CD patients (figure 5B). Conclusion In this analysis of a cross-sectional study, we are able to illustrate sex-specific aspects of not only clinical courses in IBD patients but also within specific immunological responses – highlighting the importance to closely take the IBD patients sex into consideration in the upcoming era of personalized medicine.
gastroenterology & hepatology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is the impact of gender differences on disease progression, clinical manifestations and treatment effects in inflammatory bowel diseases (IBD). Specifically, researchers hope to gain an in - depth understanding of how gender - related differences affect aspects such as diagnostic delay, disease activity, quality of life and immune response in IBD patients, in order to provide more accurate guidance for personalized medicine. ### Research Background Inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), are a class of chronic intestinal diseases, characterized by diverse intestinal symptoms and having a negative impact on the quality of life of patients. There is increasing evidence that gender differences in IBD are significant, which involve multiple aspects such as disease prevalence, pathophysiology, clinical manifestations and treatment outcomes. However, for some of these factors, the existing data are contradictory, so a more in - depth understanding of the role of gender - related differences in the course of IBD is required. ### Methods In this single - center cross - sectional study, 221 IBD patients were divided into two groups according to gender (106 males and 113 females). The study evaluated the patients' personal and medical data, including disease - specific quality of life (IBDQ), disease activity of clinical parameters (such as Harvey - Bradshaw index HBI, partial Mayo score PMS) and biochemical parameters (such as C - reactive protein CRP, fecal calprotectin). In addition, the researchers also isolated and stimulated peripheral blood mononuclear cells (PBMCs) with various pathogens to test the in - vitro cytokine response of this heterogeneous IBD cohort. ### Results Through binary logistic regression analysis, it was found that for female IBD patients, diagnostic delay (p = 0.039), IBD type (p = 0.001), IBDQ (p = 0.001) and vitamin D3 - 25 - OH serum level (p = 0.035) were independently associated with disease activity; while for male IBD patients, only IBD type (p = 0.004) and IBDQ (p = 0.001) were independently associated with disease activity. Further analysis showed that the number of uses of advanced therapies (ADT) was significantly associated with disease activity in both male and female patients (male p = 0.015, female p = 0.037), but ADT was only significantly associated with diagnostic delay in female patients (p = 0.044). Regarding the treatment frequency used by patients of both genders, it was found that male patients more frequently used prednisolone (Mann - Whitney - U test, p = 0.009) and 5 - aminosalicylic acid (p = 0.004). In the cytokine response of PBMCs after being stimulated by different pathogens, the interferon - γ level in male CD patients showed a significant trend (p < 0.05), and a significant negative correlation between interferon - γ level and CD activity was only found in male CD patients. ### Conclusions Through the analysis of this cross - sectional study, the researchers have demonstrated gender - specific differences not only in the clinical course but also in specific immune responses in IBD patients, emphasizing the necessity of considering the gender of IBD patients in the era of personalized medicine.